Search Results
Your search for The ASCO matches 20656 pages
Showing 301 - 350Phase II Study Shows Activity for Novel Targeted Agent in KRAS G12C–Mutated NSCLC
The oral KRAS G12C inhibitor glecirasib has emerged as a therapeutic option for previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC). It may potentially improve efficacy and tolerability compared with current U.S. Food and Drug Administration–approved agents, according to data...
Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions
A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...
Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting
The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentuximab vedotin has also shown efficacy and safety in combination with lenalidomide and rituximab in...
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoadjuvant chemoradiotherapy CROSS regimen. The results were presented during the Plenary Session of...
Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology
When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patients. In such cases, patients may seek legal recourse through medical malpractice lawsuits, creating...
Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...
Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy
A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...
Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period., according to a recent study published by Ahmed et al in...
Eliminating Racial Disparities in Colorectal Cancer Screening
Eliminating racial disparities in colorectal cancer testing may reduce the rate of colorectal cancer incidence and mortality among Black patients in the United States, according to a recent study published by Alagoz et al in the Journal of the National Cancer Institute. Background Although both the ...
Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment
Kristin Rojas, MD, FACS, of the University of Miami, shares key points from her discussion on improving sexual health during breast cancer treatment. Dr. Rojas is an Associate Professor of Surgery in the DeWitt Daughtry Family Department of Surgery, Division of Surgery, Miller School of Medicine at ...
Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?
Joseph A. Sparano, MD, FACP, of Icahn School of Medicine at Mount Sinai, discusses his presentation on premenopausal patients with hormone receptor–positive early breast cancer. Dr. Sparano is the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics, Chief of the Division of Hematology...
Novel Target Identified for Treating HTLV-1–Associated Diseases
Blocking the tyrosine kinase KDR could lead to cell death caused by the degradation of the TAX viral protein, thereby treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1), according to a recent study published by Mohanty et al in Nature Communications. Background HTLV-1 is...
AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials
Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...
Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates
Paolo Tarantino, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Tarantino is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and...
Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on novel therapies targeting the estrogen receptor. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research...
Liquid Biopsy May Enable Monitoring of Disease Evolution in Patients With Metastatic Prostate Cancer
DNA/RNA material contained in circulating extracellular vesicles secreted into the blood stream by tumor cells may capture cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a recent study published by Casanova et al in Cancer Cell. Background...
Panel Issues First Guidelines to Prevent Anal Cancer in Patients With HIV
Researchers have introduced the first screening and treatment recommendations to prevent anal cancer in patients with the human immunodeficiency virus (HIV), according to new guidelines based on the results of a 2022 study published by Palefsky et al in The New England Journal of Medicine....
Can Living in a Disadvantaged Area Increase the Risk of Aggressive Prostate Cancer?
Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, new research suggests, which in turn may contribute to higher rates of aggressive prostate cancer in African American men. These findings were published by Boyle et al in JAMA Network Open....
Are Eligible Breast Cancer Survivors Receiving Genetic Testing?
Researchers have found that many eligible breast cancer survivors may not be receiving genetic counseling and testing, according to a recent study published by Katz et al in the Journal of Clinical Oncology. Background A growing proportion of cancer treatment and survivorship care relies on...
Uncovering the Genetic Risk of Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Some patients with a genetic predisposition for cancer may not qualify for genetic screenings under the current guidelines, according to a recent study published by Samadder et al in JCO Precision Oncology. Researchers are investigating how to advance personalized medicine and tailor prevention and ...
Overcoming the Disparity in Cancer Incidence and Mortality Rates Among Alaska Native Individuals
Research has consistently shown that Native American and Alaska Native individuals are among the most underserved minority populations in the United States and are disproportionately affected by cancer. The results from a 50-year report by the Alaska Native Tribal Health Consortium’s Alaska Native...
Heather McArthur, MD, MPH, on Immunotherapy for High-Risk, Early-Stage Breast Cancer
Heather McArthur, MD, MPH, talks about immunotherapy for high-risk, early-stage breast cancer. Dr. McArthur is Associate Professor in the Department of Internal Medicine and Clinical Director of the Breast Cancer Program at Simmons Cancer Center at UT Southwestern Medical Center, Houston. She...
Aditya Bardia, MD, MPH, FASCO, on the Current and Future Landscape of Antibody-Drug Conjugates
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational...
Testosterone Therapy May Protect Against Breast Cancer in Transmasculine Patients
Gender-affirming testosterone therapy may have a potential protective benefit in transmasculine patients at risk of breast cancer, according to a recent study published by Heng et al in Breast Cancer Research. Background To treat their gender dysphoria, some transmasculine patients undergo...
Donor Socioeconomic Status May Influence Outcomes in Hematopoietic Cell Transplantation
Investigators have demonstrated that the socioeconomic status of cell donors may impact the health outcomes of patients with hematologic malignancies who undergo hematopoietic cell transplantation, according to a recent study published by Turcotte et al in PNAS. Study Methods and Results In the...
Neha Vapiwala, MD, FACR, FASTRO, FASCO, Voted President-Elect of ASTRO
The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO’s Board of Directors: Neha Vapiwala, MD, FACR, FASTRO, FASCO, President-Elect Jean Wright, MD, FASTRO, Clinical Affairs and Quality Council Vice Chair Andrea Ng, MD, MPH, FASTRO,...
New Imaging Guidelines for Head and Neck Cancers Published
Researchers have developed new imaging guidelines, representing a major shift in the management of patients with head and neck cancers, according to a study published by Henson et al in The Lancet Oncology. The guidelines may lay the foundation for these patients to be treated with tailored...
Electronic Health Record–Based Prompt May Help Reduce Breast Cancer Overtreatment
Researchers have developed a novel prompt, embedded in electronic health records, to flag older patients with early-stage breast cancer who may be at risk of unnecessary sentinel lymph node biopsy, according to a recent study published by Carleton et al in JAMA Surgery. Background “In breast...
Long-Term Survival Possible After Liver Transplant for Colorectal Liver Metastases
In selected patients with unresectable colorectal liver metastases, liver transplantation plus chemotherapy significantly boosted overall survival as compared with chemotherapy alone in the multicenter, European TRANSMET trial, presented at the 2024 ASCO Annual Meeting.1 The combined approach led...
A Role for Avelumab in Triple-Negative Breast Cancer?
In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly improve overall survival and risk of distant disease–free survival events. The results from the...
New Study Demonstrates Safe, Successful Pregnancy May Be Possible Following Allo-HCT
Female patients may become pregnant and give birth to healthy children despite treatment-related fertility challenges following allogeneic hematopoietic cell transplantation (allo-HCT), according to a recent study published by Sockel et al in Blood. The findings highlighted the need for increased...
Hormone-Modulating Therapy May Be Linked to Lower Dementia Risk in Patients With Breast Cancer
Hormone-modulating therapy used to treat patients with breast cancer may be associated with a 7% lower risk of developing Alzheimer’s disease and related dementias later in life, according to a recent study published by Cai et al in JAMA Network Open. Background About 67% of patients with breast...
Out-of-Pocket Costs From Diagnostic Testing After Prostate Cancer Screening
Prostate-specific antigen (PSA) screening aims to identify patients who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive—and expensive—diagnostic testing to establish a diagnosis. New research reveals that the out-of-pocket costs for such...
UK-Based Survey Finds Cancer Is the Leading Health Concern Among the Public
A new survey conducted in the United Kingdom found two-thirds of the public say they are very or somewhat worried about being told they have cancer—a higher percentage than for any other medical condition, including dementia and having a heart attack—according to polling released today. The...
High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem
Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications. Background Melanoma of the skin is the fifth most common cancer type in the...
Novel Immunotherapy Approach in Metastatic Solid Tumors
A novel personalized cellular immunotherapy approach may be effective at treating certain patients with metastatic solid tumors, according to early findings from a recent study published by Parkhurst et al in Nature Medicine. Background Chimeric antigen receptor (CAR) T-cell therapy has already...
40% of Cancer Cases and Almost Half of All Cancer Deaths in the United States Linked to Modifiable Risk Factors
A recent study led by researchers at the American Cancer Society has found that 4 in 10 cancer cases and about half of all cancer deaths in adults aged 30 and older in the United States (or 713,340 cancer cases and 262,120 cancer deaths in 2019) may be attributed to modifiable risk factors,...
RNAs May Help to Identify Patients With Stage II Colorectal Cancer Who May Benefit From Adjuvant Chemotherapy
Investigators have assessed whether RNAs can be used as a biomarker to predict which patients with stage II colorectal cancer may benefit from postsurgical chemotherapy, according to a recent study published by Korsgaard et al in The American Journal of Pathology. Background Colorectal cancer is...
Predicting Taxane-Induced Peripheral Neuropathy After Breast Cancer Therapy
Researchers have developed a novel tool that may help to predict the risk of experiencing peripheral neuropathy following treatment with taxanes in patients with breast cancer, according to a recent study published by Engvall et al in npj Precision Oncology. The findings may aid physicians in...
Certain Patients Diagnosed With 'Benign' Classification of Prostate Cancer May Actually Have High-Risk Disease
Recently, some experts have called for Gleason Grade Group 1 prostate cancer to be reclassified as benign. However, many patients diagnosed with this lowest grade of prostate cancer may have more aggressive disease than their biopsy alone suggests, according to a recent study published by Tilki et...
New Study May Provide Insights Into Immune System Mechanism Shared by Pregnancy and Cancer
By examining the immune system during pregnancy, researchers have uncovered the mechanism that may contribute to oncofetal immune tolerance, according to a recent study published by Yu et al in Cell. Background “In pregnancy, the immune system does not reject the growing fetus, so we know there...
Having Acute Lymphoblastic Leukemia Took Away My Fear of Death
On May 30, 2017, 9 days before I turned 19 and soon after I had completed my sophomore year at college, I was diagnosed with aggressive acute lymphoblastic leukemia. But getting to the diagnosis was a tortuous process. I had been feeling fatigued and losing weight for several weeks prior to the...
Chronic Graft-vs-Host Disease: Clinical Trial Updates
Chronic graft-vs-host disease, an immune-mediated disorder that follows allogeneic hematopoietic cell transplantation (allo-HCT), is characterized by debilitating tissue injury with inflammatory and fibrotic pathology leading to significant morbidity and mortality. Historically, the treatment of...
Breaking the Silence: Addressing Sexual and Reproductive Health in Cancer Care
For patients with cancer and cancer survivors, sexual dysfunction and reproductive health concerns are often the elephant in the exam room—a significant quality-of-life issue that both patients and clinicians struggle to discuss openly and effectively. At the recent NCCN Policy Summit on Sexual and ...
Novel Antibody-Drug Conjugate Extends Survival vs Chemotherapy in Triple-Negative Breast Cancer
The antibody-drug conjugate sacituzumab tirumotecan extended overall survival as well as progression-free survival vs chemotherapy in patients with previously treated triple-negative breast cancer, according to the results of OptiTROP-Breast01, a phase III study presented at the 2024 ASCO Annual...
AMA House of Delegates Adopts Record Six ASCO-Led Resolutions
Delegates from the Association for Clinical Oncology (ASCO) participated in the 2024 Annual Meeting of the American Medical Association (AMA) House of Delegates (HOD) on June 7 to 12 in Chicago. ASCO created and was the primary sponsor of six resolutions that the AMA HOD adopted as policy, an...
ASCO Issues New Guidance on Vaccinations for Adults With Cancer
A new ASCO Clinical Practice Guideline recommends several vaccinations (eg, seasonal, herpes zoster, human papillomavirus [HPV], and others) for adults with solid or hematologic malignancies because of heightened infection risks from vaccine-preventable illnesses.1 The guideline covers the...
Stiripentol Could Prolong Efficacy of Chemotherapy in Patients With Gastric Cancer
Targeting lactate with the epilepsy drug stiripentol may reverse chemotherapy resistance in patients with gastric cancer, according to a recent study published by Chen et al in Nature. Background Chemotherapy attacks cancer cells by damaging their DNA. The cancer cells then try to rapidly repair...
Infection Risk in Patients With Mantle Cell Lymphoma
Patients with mantle cell lymphoma may be susceptible to certain diseases and may benefit from evaluation for the risk of infection, according to a recent study published by Abalo in HemaSphere. Background “Patients [with mantle cell lymphoma] live with an increased risk of infections for many...
Survivorship Standards at Commission on Cancer–Accredited Cancer Care Facilities
Only a minority of adult cancer survivors may have access to specialized survivorship services such as those addressing fertility and sexual health issues, and having survivorship standards in place may help cancer centers better provide services that meet the distinct needs of these patients,...
